Literature DB >> 10581198

Hyperglycemia impairs the insulin signaling step between PI 3-kinase and Akt/PKB activations in ZDF rat liver.

M Nawano1, K Ueta, A Oku, K Arakawa, A Saito, M Funaki, M Anai, M Kikuchi, Y Oka, T Asano.   

Abstract

Akt/PKB activation is reportedly essential for insulin-induced glucose metabolism in the liver. During the hypoinsulinemic and hyperglycemic phase in the Zucker diabetic fatty (ZDF) rat liver, insulin-induced phosphorylations of the insulin receptor (IR) and insulin receptor substrate (IRS)-1/2 were significantly enhanced. Similarly, phosphatidylinositol (PI) 3-kinase activities associated with IRS-1/2 were markedly increased in ZDF rat liver compared with those in the control lean rat liver. However, interestingly, insulin-induced phosphorylation and kinase activation of Akt/PKB were severely suppressed. The restoration of normoglycemia by sodium-dependent glucose transporter (SGLT) inhibitor to ZDF rats normalized elevated PI 3-kinase activation and phosphorylation of IR and IRS-1/2 to lean control rat levels. In addition, impaired insulin-induced Akt/PKB activation was also normalized. These results suggest that chronic hyperglycemia reduces the efficiency of the activation step from PI 3-kinase to Akt/PKB kinase and that this impairment is the molecular mechanism underlying hyperglycemia-induced insulin resistance in the liver. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10581198     DOI: 10.1006/bbrc.1999.1797

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095.

Authors:  K Arakawa; T Ishihara; A Oku; M Nawano; K Ueta; K Kitamura; M Matsumoto; A Saito
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 2.  Vascular signaling pathways in the metabolic syndrome.

Authors:  Hiromi Rakugi; Kei Kamide; Toshio Ogihara
Journal:  Curr Hypertens Rep       Date:  2002-04       Impact factor: 5.369

3.  Limited therapeutic effect of N-acetylcysteine on hepatic insulin resistance in an experimental model of alcohol-induced steatohepatitis.

Authors:  Mashiko Setshedi; Lisa Longato; Dennis R Petersen; Martin Ronis; William C Chen; Jack R Wands; Suzanne M de la Monte
Journal:  Alcohol Clin Exp Res       Date:  2011-07-25       Impact factor: 3.455

4.  Insulin-induced cortical actin remodeling promotes GLUT4 insertion at muscle cell membrane ruffles.

Authors:  P Tong; Z A Khayat; C Huang; N Patel; A Ueyama; A Klip
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

5.  Rosiglitazone, an agonist of peroxisome-proliferator-activated receptor gamma (PPARgamma), decreases inhibitory serine phosphorylation of IRS1 in vitro and in vivo.

Authors:  Guoqiang Jiang; Qing Dallas-Yang; Subarna Biswas; Zhihua Li; Bei B Zhang
Journal:  Biochem J       Date:  2004-01-15       Impact factor: 3.857

Review 6.  Modulation of insulin action.

Authors:  L Pirola; A M Johnston; E Van Obberghen
Journal:  Diabetologia       Date:  2004-01-13       Impact factor: 10.122

7.  SIRT1 overexpression attenuates offspring metabolic and liver disorders as a result of maternal high-fat feeding.

Authors:  Long T Nguyen; Hui Chen; Amgad Zaky; Carol Pollock; Sonia Saad
Journal:  J Physiol       Date:  2018-10-31       Impact factor: 5.182

8.  Intracellular segregation of phosphatidylinositol-3,4,5-trisphosphate by insulin-dependent actin remodeling in L6 skeletal muscle cells.

Authors:  Nish Patel; Assaf Rudich; Zayna A Khayat; Rami Garg; Amira Klip
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

9.  PAQR3 modulates insulin signaling by shunting phosphoinositide 3-kinase p110α to the Golgi apparatus.

Authors:  Xiao Wang; Lingdi Wang; Lu Zhu; Yi Pan; Fei Xiao; Weizhong Liu; Zhenzhen Wang; Feifan Guo; Yong Liu; Walter G Thomas; Yan Chen
Journal:  Diabetes       Date:  2012-10-18       Impact factor: 9.461

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.